ELINAFIDA, ESTADO ACTUAL DE UNA NAFTALIMIDA ACTIVA
Columnista Experta de SIIC Tamila L. Kindwall-Keller
en colaboración con
Miguel A. Villalona-Calero , Medical Oncologist, Associate Professor of Medicine. Division of Hematology/Oncology. Arthur G. James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University
Primera edición en siicsalud:
8 de abril, 2003
Sección Artículos originales,
subsección
Expertos de Iberoamérica,
página
/des/expertocompleto.php/20110
Especialidad principal:
Farmacología
Especialidades relacionadas:
Medicina Interna,Oncología,
Hypermethylation induced decrease in Sp1/Sp3 binding is associated with reduced p21Cip1 expression in response to depsipeptide treatment, Molecular and Cellular Biology. (Accepted Pending Revisions) :
Lung specific expression of mutant p53 (273H) results in high frequency of lung adenocarcinoma in transgenic mice, Oncogene (In Press) :
Mitomycin C as a Modulator of Irinotecan Anticancer Activity, Oncology 16(16):21-25, 2002
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies, Clinical Cancer Research 8:2142-2148, 2002
Pharmaco-biologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies, Journal of Clinical Oncology 20:2616-2623, 2002
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, with paclitaxel in patients with chemorefractory small cell lung cancer, Annals of Oncology 13:539-45, 2002
Detection of transgene and host endogenous homologous gene expression and silencing using RT-PCR-Heteroduplex technique in transgenic animal models, Biotechniques 33:58-66, 2002
A Phase I And Pharmacokinetic Study of ET-743, a Novel DNA Minor Groove Binder of Marine Origin Administered as a 1-hour infusion daily x 5 Days, Clinical Cancer Research 8:75-85, 2002
Tamila L. Kindwall-Keller
